Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer

E. Heitzer, D. van den Broek, M. G. Denis, P. Hofman, M. Hubank, F. Mouliere, L. Paz-Ares, E. Schuuring, H. Sültmann, G. Vainer, E. Verstraaten, L. de Visser, D. Cortinovis

Research output: Contribution to journalReview articlepeer-review

Abstract

Background: Liquid biopsy (LB) is a rapidly evolving diagnostic tool for precision oncology that has recently found its way into routine practice as an adjunct to tissue biopsy (TB). The concept of LB refers to any tumor-derived material, such as circulating tumor DNA (ctDNA) or circulating tumor cells that are detectable in blood. An LB is not limited to the blood and may include other fluids such as cerebrospinal fluid, pleural effusion, and urine, among others. Patients and methods: The objective of this paper, devised by international experts from various disciplines, is to review current challenges as well as state-of-the-art applications of ctDNA mutation testing in metastatic non-small-cell lung cancer (NSCLC). We consider pragmatic scenarios for the use of ctDNA from blood plasma to identify actionable targets for therapy selection in NSCLCs. Results: Clinical scenarios where ctDNA mutation testing may be implemented in clinical practice include complementary tissue and LB testing to provide the full picture of patients’ actual predictive profiles to identify resistance mechanism (i.e. secondary mutations), and ctDNA mutation testing to assist when a patient has a discordant clinical history and is suspected of showing intertumor or intratumor heterogeneity. ctDNA mutation testing may provide interesting insights into possible targets that may have been missed on the TB. Complementary ctDNA LB testing also provides an option if the tumor location is hard to biopsy or if an insufficient sample was taken. These clinical use cases highlight practical scenarios where ctDNA LB may be considered as a complementary tool to TB analysis. Conclusions: Proper implementation of ctDNA LB testing in routine clinical practice is envisioned in the near future. As the clinical evidence of utility expands, the use of LB alongside tissue sample analysis may occur in the patient cases detailed here.

Original languageEnglish
Article number100399
JournalESMO Open
Volume7
Issue number2
DOIs
StatePublished - Apr 2022
Externally publishedYes

Keywords

  • ctDNA mutation testing
  • non-small-cell lung cancer
  • patient scenario
  • precision oncology

Fingerprint

Dive into the research topics of 'Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this